Hypercholesterolaemia in the elderly: is drug treatment justified?

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Total serum cholesterol is a significant risk factor for coronary heart disease (CHD), particularly in middle-aged populations.
• The correlation between cholesterol and CHD incidence diminishes with increasing age.
• Low-density lipoprotein (LDL) cholesterol remains a risk factor in the elderly, while high-density lipoprotein (HDL) cholesterol retains protective effects.

Purpose of the Study:

• To evaluate the significance of cholesterol management in elderly populations.
• To assess the potential benefits of new cholesterol-modulating therapies in older individuals.

Main Methods:

• Review of epidemiological data, including the Framingham study.
• Consideration of emerging pharmacological agents like HMG CoA reductase inhibitors.

Main Results:

• LDL cholesterol's impact as a CHD risk factor is reduced in the elderly.
• HDL cholesterol remains a significant protective factor in old age.
• New HMG CoA reductase inhibitors demonstrate efficacy in lowering LDL and increasing HDL cholesterol with good patient compliance.

Conclusions:

• Traditional rationale for non-intervention in elderly cholesterol management is challenged by new therapeutic options.
• Drug therapy with HMG CoA reductase inhibitors may be beneficial for selected elderly patients with dyslipidemia.
• Further investigation into the risk-benefit profile of cholesterol-lowering drugs in the elderly is warranted.